NCT00026377View on ClinicalTrials.gov

SU5416 Plus Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

November 30, 2001

Primary Completion Date

March 31, 2002

Study Completion Date

April 30, 2003

Conditions
Prostate Cancer
Interventions
DRUG

bicalutamide

50 mg daily for 1 month

DRUG

flutamide

250 mg 3 times daily for 1 month

DRUG

goserelin acetate

3.6 mg once a month for 4 months

DRUG

leuprolide acetate

7.5 mg once a month for 4 months

DRUG

SU5416

IV infusion at assigned dose

RADIATION

radiation therapy

daily for 5 days each week

Trial Locations (3)

60525

LaGrange Memorial Hospital, LaGrange

60612

Radiation Oncology, Chicago

60637-1470

University of Chicago Cancer Research Center, Chicago

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Chicago

OTHER

NCT00026377 - SU5416 Plus Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer | Biotech Hunter | Biotech Hunter